Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
A study concerning viral kinetic with 10 co-infected HIV-HCV patients on treatment with
peginterferon alfa-2a + ribavirin o IFN + ribavirin was reported in Conference on
Retroviruses and Opportunistic Infections 2002 by Dr. Torriani shown half-life of HCV virions
and the viral clearance was larger than mono-infected patients.
The doubt is if this difference in viral kinetic of HIV-HCV co-infected patients versus
mono-infected is related with the loss of profited on treatment.
In the APRICOT trial patients genotype 2/3 were treated for 48 weeks and the relapse rates
was only 2%.
The present study want to evaluate is the treatment extent for 24 weeks more in patients
genotype 1 and/or 4 will be improve the percentage of patients with viral clearance at the
end of the follow-up period, to prevent relapsed in patients with response at the end of
treatment.
Patients will be randomized to received 180 µg/week of peginterferon alfa-2a + 1000-1200
mg/day of ribavirin during 24 weeks more or control.